profit from every €100 of sales.
€0€100
Boiron SA
€19.05-1.04% today
-37.2% since Dec 22, 25
1-year low €16.901-year high €30.65
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €10.13 for every €1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Boiron SA sold, what it kept, and what it did with the cash.
Sales went from €534 million in 2022 to €501 million in 2025, with €32.6 million of profit last year.
SalesProfit
Boiron SA handed back 70% of the cash it generated last year.
€21M
Free cash flow 2025€30M
Bought back its own shares€43,000
Paid as dividends€21M
Cash vs. debt€79M vs. €31M
Boiron SA vs. similar companies
Boiron SA grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Boiron SA | 10.1× · Cheap | ||
 Merck KGaA | 24.8× · Fair price | ||
 Takeda Pharmaceutical | 101.0× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.1× · Expensive |
AI analysis
An AI analyst reads Boiron SA's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 534 | 493 | 488 | 501 | |
| 380 | 358 | 359 | 366 | |
| 57 | 41 | 36 | 36 | |
| 77 | 74 | 58 | 63 | |
| 45 | 36 | 11 | 33 | |
| 2.57 | 2.06 | 0.65 | 1.88 | |
| 71.1% | 72.6% | 73.6% | 73.0% | |
| 10.6% | 8.3% | 7.3% | 7.3% | |
| 8.4% | 7.3% | 2.3% | 6.5% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 789 | 590 | 576 | 603 |
| Cash | 251 | 74 | 65 | 79 |
| Total debt | 22 | 14 | 15 | 31 |
| Total liabilities | 232 | 199 | 198 | 210 |
| 558 | 394 | 378 | 393 | |
| 17 | 17 | 17 | 17 | |
| 7.7% | 8.8% | 3.0% | 7.8% | |
| 8.0% | 9.1% | 3.0% | 8.3% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 59 | 45 | 40 | 53 | |
| 19 | 18 | 16 | 24 | |
| 40 | 27 | 24 | 30 | |
| Dividends paid | 17 | 199 | 23 | 21 |
| 6 | 0 | 0 | 0 | |
| – | – | – | – |
Valuation
- 10.1×
- –
- –
- 1.2×
- 0.7×
- 11.1×
- 4.5×
- 9.0%
- 9.9%
- 6.3%
Profitability
- 73.0%
- 7.3%
- 6.5%
- –
- 7.8%
- 6.8%
- –
- –
- –
- –
Growth
- −2.1%
- −9.9%
- –
- –
- −0.1%
Financial health
- -0.8×
- 0.08
- –
- 39.6×
- 2.22
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 40%of 952
Bottom 44%of 883
Top 10%of 576
Bottom 11%of 870
Top 10%of 985
6.3%of the share price, paid each year
On $1,000 invested$63a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
63.8% of its profit
Room to growStretchedMore than it earns: 70.1%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
68Pass
Benjamin Graham
85Pass
Philip Fisher
47No pass
Peter Lynch
22No pass
Joel Greenblatt
53No pass
Charlie Munger
49No pass
Terry Smith
43No pass
Questions about Boiron SA
Is Boiron SA a good stock to buy?
A business with weak numbers, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Boiron SA AI analysis
What does Boiron SA do?
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Messimy, France, with 2,364 employees.
Does Boiron SA pay a dividend?
Yes. At today's price the dividend is 6.3% a year, about 64% of its yearly profit. In 2025 it paid out €20.8 million in dividends.
Is Boiron SA stock halal?
Yes. Boiron SA passes our halal screen: its business is permitted and its debt is 10% of its market value, under the 30% limit. How we check
Who are Boiron SA's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Boiron SA's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.